Madam Speaker, there are two considerations.
First, the new intellectual property rules, everybody acknowledges, will delay the introduction of generics to market, which will no doubt have an impact on rising health care costs in Canada. Second, and this goes to my question earlier about the ISDS procedure, but ISDS under the TPP may result in companies being able to sue Canada for bringing in national programs, including perhaps a national pharmacare program.
The Minister of International Trade says that CETA represents the gold standard in ISDS, which means the TPP represents the bronze standard. I do not think Canada should settle for bronze when it comes to a trade agreement.